Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Report highlights significant improvements in adolescent well-being in India
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Subscribe To Our Newsletter & Stay Updated
